GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aura Biosciences Inc (NAS:AURA) » Definitions » ROC (Joel Greenblatt) %

Aura Biosciences (Aura Biosciences) ROC (Joel Greenblatt) % : -387.95% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Aura Biosciences ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Aura Biosciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -387.95%.

The historical rank and industry rank for Aura Biosciences's ROC (Joel Greenblatt) % or its related term are showing as below:

AURA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -721.23   Med: -616.15   Max: -350.89
Current: -361.62

During the past 5 years, Aura Biosciences's highest ROC (Joel Greenblatt) % was -350.89%. The lowest was -721.23%. And the median was -616.15%.

AURA's ROC (Joel Greenblatt) % is ranked worse than
51.34% of 1459 companies
in the Biotechnology industry
Industry Median: -330.28 vs AURA: -361.62

Aura Biosciences's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Aura Biosciences ROC (Joel Greenblatt) % Historical Data

The historical data trend for Aura Biosciences's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aura Biosciences ROC (Joel Greenblatt) % Chart

Aura Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
-665.80 -616.15 -721.23 -369.45 -350.89

Aura Biosciences Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -296.72 -317.78 -331.22 -427.03 -387.95

Competitive Comparison of Aura Biosciences's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Aura Biosciences's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aura Biosciences's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aura Biosciences's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Aura Biosciences's ROC (Joel Greenblatt) % falls into.



Aura Biosciences ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 5.644) - (5.232 + 0 + 4.438)
=-4.026

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 9.375) - (4.442 + 0 + 2.48)
=2.453

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Aura Biosciences for the quarter that ended in Mar. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-89.252/( ( (22.004 + max(-4.026, 0)) + (21.555 + max(2.453, 0)) )/ 2 )
=-89.252/( ( 22.004 + 24.008 )/ 2 )
=-89.252/23.006
=-387.95 %

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aura Biosciences  (NAS:AURA) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Aura Biosciences ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Aura Biosciences's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aura Biosciences (Aura Biosciences) Business Description

Traded in Other Exchanges
N/A
Address
85 Bolton Street, Cambridge, MA, USA, 02140
Aura Biosciences Inc is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system to create long-lasting anti-tumor immunity.
Executives
Matrix Capital Management Company, Lp 10 percent owner 1000 WINTER STREET, C/O MATRIX CAPITAL MANAGEMENT, WALTHAM MA 02451
David Michael Johnson director C/O ZENTALIS PHARMACEUTICALS, LLC, 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Julie B Feder officer: Chief Financial Officer C/O VERASTEM, INC., 117 KENDRICK STREET, SUITE 500, NEEDHAM MA 02494
De Los Pinos Elisabet director, officer: Chief Executive Officer C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Janet Jill Hopkins officer: See Remarks C/O AURA BIOSCIENCES, INC., 80 GUEST STREET, BOSTON MA 01235
Cadmus Rich officer: See Remarks C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Rosch Mark De officer: Chief Operating Officer C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Medicxi Ventures Management (jersey) Ltd 10 percent owner C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG
Medicxi Growth I Lp 10 percent owner C/O ELIAN FUND SERVICES (JERSEY) LIMITED, 44 ESPLANADE, ST HELIER Y9 JE4 9WG
Giovanni Mariggi director C/O AURA BIOSCIENCES, INC., 85 BOLTON STREET, CAMBRIDGE MA 02140
Medicxi Growth I Gp Ltd 10 percent owner C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG
Medicxi Growth Co-invest I Lp 10 percent owner C/O INTERTRUST FUND SERVICES (JERSEY), 44 ESPLANADE, ST. HELIER Y9 JE4 9WG
David E. Goel 10 percent owner C/O MATRIX CAPITAL MANAGEMENT CO., LP, 1000 WINTER STREET, SUITE 4500, WALTHAM MA 02451
Karan S. Takhar director C/O ZENTALIS PHARMACEUTICALS,INC., 530 SEVENTH AVENUE, SUITE 2201, NEW YORK NY 10018
Antony C. Mattessich director C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730

Aura Biosciences (Aura Biosciences) Headlines

From GuruFocus

Aura Biosciences to Participate in Upcoming Investor Conferences

By Business Wire Business Wire 05-24-2023

Aura Biosciences to Participate in Upcoming Investor Conferences

By Business Wire Business Wire 05-25-2022